Post operative nausea and vomiting and motion sickness
Conditions
Interventions
Trade Name: STUGERON
Product Name: Cinnarizine
Pharmaceutical Form: Tablet
INN or Proposed INN: Cinnarizine
CAS Number: CAS-298-57-7
Concentration unit: mg milligram(s)
Concentration type: equal
Conce
Sponsors
Swindon & Marlborough NHS Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Female patients 2. Undergoing day case gynaecological surgery 3. Aged 18-60 years 4. ASA 1 & 2 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. Those who are unable to give informed consent. 2. Patients with gastrointestinal disease. 3. Patients with hepatic or renal disease. 4. Pregnant or lactating patients. 5. Those patients with known or suspected adverse reactions to the study drugs. 6. Patients undergoing therapeutic termination of pregnancy. 7. Patients undergoing surgery for miscarriage. 8. Obese patients (BMI>30) 9. Patients suffering from pre-operative nausea or vomiting 10. Patients receiving current oral or intramuscular steroid therapy. 11. Patients suffering severe acute anxiety reactions. 12. Patients receiving other anti-emetic drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To investigate the clinical efficacy of a single post-operative dose of cinnarizine in the prevention of post-operative nausea and vomiting associated with the journey home after day-case gynaecological surgery.;Secondary Objective: ;Primary end point(s): Nausea, Retching and Vomiting. | — |
Countries
United Kingdom
Outcome results
None listed